Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO)

Nita Katarina Frifelt Wienholtz, Casper Emil Christensen, Jeanette Halskou Haugaard, Ditte Georgina Zhang, Messoud Ashina, Jacob Pontoppidan Thyssen, Alexander Egeberg, Nita Katarina Frifelt Wienholtz, Casper Emil Christensen, Jeanette Halskou Haugaard, Ditte Georgina Zhang, Messoud Ashina, Jacob Pontoppidan Thyssen, Alexander Egeberg

Abstract

Purpose: Migraine has consistently been connected with rosacea. Commonalities in epidemiology, trigger factors and associated neuropeptides support shared aetiology and pathophysiological pathways, though underlying mechanisms remain unclear. We established two cohorts of patients diagnosed with either migraine and/or rosacea. All patients were phenotyped in regard to migraine and rosacea. In this article, we describe the baseline parameters of the cohorts. In the future, we expect that these cohorts will help uncover potential disease overlaps and allow for prolonged follow-up through national Danish health registers.

Participants: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO) are prospective cohorts based in the Capital region of Denmark. Participants for COROCO were recruited primarily through two tertiary dermatology clinics in Copenhagen, Denmark and patients for COMICO were recruited through a tertiary neurology clinic in Copenhagen, Denmark.

Findings to date: COROCO: 67.7% women (median age 51 years (interquartile range (IQR) 43.0-61.0)). Family history of migraine: 44.3%. Family history of rosacea: 45%. There were 13% who currently smoked, and 36.6% were former smokers. Regular intake of alcohol was present in 79.3% (median 4 items/week (IQR 1.0-9.0)). Median body mass index (BMI): 25.7 (IQR 23.1-29.0). Median Dermatology Life Quality Index (DLQI): 2 (IQR 1-5).

Comico: 88.5% women (median age 41 years (IQR 29.5-51.0)). Family history of migraine: 73.4%. Family history of rosacea: 18.4%. There were 17.1% who currently smoked, and 26.0% former smokers. Regular intake of alcohol was present in 62.2% (median intake: 2 item/week (IQR 1.0-3.0)). Median BMI was 24.6 (IQR 21.5-28.2). Median DLQI was 1 (IQR 0-2).

Future plans: COROCO and COMICO serve as strong data sources that will be used for future studies on rosacea and migraine with focus on risk factors, occurrence, treatment, natural history, complications, comorbidities and prognosis.

Trial registration number: ClinicalTrials.gov Registry (NCT03872050).

Keywords: cohort study; epidemiology; migraine; prospective; rosacea.

Conflict of interest statement

Competing interests: NKFW has received personal fees from Novartis and the Kgl Hofbundtmager Aage Bang Foundation. CEC received personal fees from Teva and acts as consultant for Teva. JHH and DGZ declare no conflicts relevant to the manuscript. MA is a consultant, speaker or scientific advisor for Alder, Allergan, Amgen, Eli Lilly, Lundbeck, Novartis, and Teva, primary investigator for Alder, Allergan, Amgen, Eli Lilly, Novartis and Teva trials. MA has no ownership interest and does not own stocks of any pharmaceutical company. MA serves as associate editor of Cephalalgia, associate editor of Headache, associate editor of the Journal of Headache and Pain. MA is President of the International Headache Society. JPT has attended advisory boards for Sanofi-Genzyme, Eli Lilly & Co, Pfizer, Abbvie, and Union Therapeutics, and received honoraria as a speaker from LEO Pharma, Regeneron, Abbvie, and Sanofi-Genzyme, and has been an investigator for Sanofi-Genzyme, Eli Lilly & Co, LEO Pharma, Pfizer, and Abbvie. AE has received research funding from Pfizer, Eli Lilly, the Danish National Psoriasis Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from Almirall, Leo Pharma, Samsung Bioepis Co., Ltd. Pfizer, Eli Lilly & Co, Novartis, Galderma, Dermavant, Bristol-Myers Squibb, and Janssen Pharmaceuticals.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Flowchart detailing enrolment in Copenhagen Rosacea Cohort. EMR, electronic medical records.
Figure 2
Figure 2
Flowchart detailing enrolment in Copenhagen Migraine Cohort.

References

    1. Christensen CE, Andersen FS, Wienholtz N, et al. . The relationship between migraine and rosacea: systematic review and meta-analysis. Cephalalgia 2018;38:1387–98. 10.1177/0333102417731777
    1. Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013;69:S15–26. 10.1016/j.jaad.2013.04.045
    1. Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia 2007;27:394–402. 10.1111/j.1468-2982.2007.01303.x
    1. Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, burden, and comorbidity. Neurol Clin 2019;37:631–49. 10.1016/j.ncl.2019.06.001
    1. Steiner TJ, Scher AI, Stewart WF, et al. . The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia 2003;23:519–27. 10.1046/j.1468-2982.2003.00568.x
    1. Lipton RB, Bigal ME, Diamond M, et al. . Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343–9. 10.1212/01.wnl.0000252808.97649.21
    1. Brandes JL. Global trends in migraine care: results from the maze survey. CNS Drugs 2002;16 Suppl 1:13–18. 10.2165/00023210-200216001-00003
    1. Gether L, Overgaard LK, Egeberg A, et al. . Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol 2018;179:282–9. 10.1111/bjd.16481
    1. Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol 2013;69:S27–35. 10.1016/j.jaad.2013.04.043
    1. Gallo RL, Granstein RD, Kang S, et al. . Standard classification and pathophysiology of rosacea: the 2017 update by the National rosacea Society expert Committee. J Am Acad Dermatol 2018;78:148–55. 10.1016/j.jaad.2017.08.037
    1. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol 2018;17:174–82. 10.1016/S1474-4422(17)30435-0
    1. Vollesen ALH, Ashina M. Pacap38: emerging drug target in migraine and cluster headache. Headache 2017;57 Suppl 2:56–63. 10.1111/head.13076
    1. Khan S, Olesen A, Ashina M. Cgrp, a target for preventive therapy in migraine and cluster headache: systematic review of clinical data. Cephalalgia 2019;39:374–89. 10.1177/0333102417741297
    1. Holmes AD, Steinhoff M. Integrative concepts of rosacea pathophysiology, clinical presentation and new therapeutics. Exp Dermatol 2017;26:659–67. 10.1111/exd.13143
    1. Egeberg A, Ashina M, Gaist D, et al. . Prevalence and risk of migraine in patients with rosacea: a population-based cohort study. J Am Acad Dermatol 2017;76:454–8. 10.1016/j.jaad.2016.08.055
    1. Tan SG, Cunliffe WJ. Rosacea and migraine. Br Med J 1976;1:21. 10.1136/bmj.1.6000.21
    1. Berg M, Lidén S. An epidemiological study of rosacea. Acta Derm Venereol 1989;69:419–23.
    1. Spoendlin J, Voegel JJ, Jick SS, et al. . Migraine, triptans, and the risk of developing rosacea: a population-based study within the United Kingdom. J Am Acad Dermatol 2013;69:399–406. 10.1016/j.jaad.2013.03.027
    1. Ramelet AA. Rosacea: a reaction pattern associated with ocular lesions and migraine? Arch Dermatol 1994;130:1448. 10.1001/archderm.1994.01690110118022
    1. Berg M, Lidén S. Postmenopausal female rosacea patients are more disposed to react with migraine. Dermatology 1996;193:73–4. 10.1159/000246214
    1. WHO ICD-10 [Internet], 2019. Available:
    1. Rosacea Clinical Scorecard [Internet], 2019. Available: [Accessed 2019 Jun 29].
    1. Gervil M, Ulrich V, Olesen J, et al. . Screening for migraine in the general population: validation of a simple questionnaire. Cephalalgia 1998;18:342–8. 10.1046/j.1468-2982.1998.1806342.x
    1. Wienholtz N, Christensen CE, Egeberg A, et al. . Vasomotor reactions in the face and head of patients with migraine.. Cephalalgia Reports. 2018;1.
    1. Sinikumpu S-P, Huilaja L, Auvinen J, et al. . The association between low grade systemic inflammation and skin diseases: a cross-sectional survey in the Northern Finland birth cohort 1966. Acta Derm Venereol 2018;98:65–9. 10.2340/00015555-2795
    1. Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol 2019;15:483–90. 10.1038/s41582-019-0216-y
    1. Gormley P, Anttila V, Winsvold BS, et al. . Meta-Analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nat Genet 2016;48:856–66. 10.1038/ng.3598
    1. Chang ALS, Raber I, Xu J, et al. . Assessment of the genetic basis of rosacea by genome-wide association study. J Invest Dermatol 2015;135:1548–55. 10.1038/jid.2015.53
    1. Aponte JL, Chiano MN, Yerges-Armstrong LM, et al. . Assessment of rosacea symptom severity by genome-wide association study and expression analysis highlights immuno-inflammatory and skin pigmentation genes. Hum Mol Genet 2018;27:2762–72. 10.1093/hmg/ddy184
    1. Green RC, Berg JS, Grody WW, et al. . ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine 2013;15:565–74. 10.1038/gim.2013.73
    1. Ho TW, Edvinsson L, Goadsby PJ. Cgrp and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 2010;6:573–82. 10.1038/nrneurol.2010.127
    1. Woo YR, Lim JH, Cho DH, et al. . Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int J Mol Sci 2016;17:1562–23. 10.3390/ijms17091562
    1. Dodick DW, Ashina M, Brandes JL, et al. . Arise: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 2018;38:1026–37. 10.1177/0333102418759786
    1. Russell MB, Fenger K, Olesen J. The family history of migraine. direct versus indirect information. Cephalalgia 1996;16:156–60. 10.1046/j.1468-2982.1996.1603156.x
    1. Lateef T, Cui L, Nakamura E, et al. . Accuracy of family history reports of migraine in a community-based family study of migraine. Headache 2017;66:407–12.
    1. Abram K, Silm H, Maaroos H-I, et al. . Risk factors associated with rosacea. J Eur Acad Dermatol Venereol 2010;24:565–71. 10.1111/j.1468-3083.2009.03472.x
    1. Rainer BM, Fischer AH, Luz Felipe da Silva D, et al. . Rosacea is associated with chronic systemic diseases in a skin severity-dependent manner: results of a case-control study. J Am Acad Dermatol 2015;73:604–8. 10.1016/j.jaad.2015.07.009
    1. Tan J, Schöfer H, Araviiskaia E, et al. . Prevalence of rosacea in the general population of Germany and Russia - The RISE study. J Eur Acad Dermatol Venereol 2016;30:428–34. 10.1111/jdv.13556
    1. Tizek L, Schielein MC, Seifert F, et al. . Skin diseases are more common than we think: screening results of an unreferred population at the Munich Oktoberfest. J Eur Acad Dermatol Venereol 2019;33:1421–8. 10.1111/jdv.15494
    1. Spoendlin J, Voegel JJ, Jick SS, et al. . A study on the epidemiology of rosacea in the U.K. Br J Dermatol 2012;167:598–605. 10.1111/j.1365-2133.2012.11037.x
    1. Li W-Q, Zhang M, Danby FW, et al. . Personal history of rosacea and risk of incident cancer among women in the US. Br J Cancer 2015;113:520–3. 10.1038/bjc.2015.217
    1. Li S, Cho E, Drucker AM, et al. . Cigarette smoking and risk of incident rosacea in women. Am J Epidemiol 2017;186:38–45. 10.1093/aje/kwx054
    1. Duman N, Ersoy Evans S, Atakan N. Rosacea and cardiovascular risk factors: a case control study. J Eur Acad Dermatol Venereol 2014;28:1165–9. 10.1111/jdv.12234
    1. Kucukunal A, Altunay I, Arici JE, et al. . Is the effect of smoking on rosacea still somewhat of a mystery? Cutan Ocul Toxicol 2016;35:110–4. 10.3109/15569527.2015.1046184
    1. Weiss E, Katta R. Diet and rosacea: the role of dietary change in the management of rosacea. Dermatol Pract Concept 2017;7:31–7. 10.5826/dpc.0704a08
    1. Bae YI, Yun S-J, Lee J-B, et al. . Clinical evaluation of 168 Korean patients with rosacea: the sun exposure correlates with the erythematotelangiectatic subtype. Ann Dermatol 2009;21:243–9. 10.5021/ad.2009.21.3.243
    1. Elewski BE, Draelos Z, Dréno B, et al. . Rosacea - global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol 2011;25:188–200. 10.1111/j.1468-3083.2010.03751.x
    1. Li S, Cho E, Drucker AM, et al. . Alcohol intake and risk of rosacea in US women. J Am Acad Dermatol 2017;76:1061–7. 10.1016/j.jaad.2017.02.040
    1. Aldrich N, Gerstenblith M, Fu P, et al. . Genetic vs environmental factors that correlate with rosacea: a cohort-based survey of twins. JAMA Dermatol 2015;151:1213–9. 10.1001/jamadermatol.2015.2230
    1. Alinia H, Tuchayi SM, Patel NU, et al. . Rosacea triggers: alcohol and smoking. Dermatol Clin 2018;36:123–6. 10.1016/j.det.2017.11.007
    1. Curnier A, Choudhary S. Rhinophyma: dispelling the myths. Plast Reconstr Surg 2004;114:351–4. 10.1097/01.PRS.0000131875.67987.69
    1. Akin Belli A, Ozbas Gok S, Akbaba G, et al. . The relationship between rosacea and insulin resistance and metabolic syndrome. Eur J Dermatol 2016;26:260–4. 10.1684/ejd.2016.2748
    1. Li S, Cho E, Drucker AM, et al. . Obesity and risk for incident rosacea in US women. J Am Acad Dermatol 2017;77:1083–7. 10.1016/j.jaad.2017.08.032
    1. Egeberg A, Hansen PR, Gislason GH, et al. . Assessment of the risk of cardiovascular disease in patients with rosacea. J Am Acad Dermatol 2016;75:336–9. 10.1016/j.jaad.2016.02.1158
    1. Hua T-C, Chung P-I, Chen Y-J, et al. . Cardiovascular comorbidities in patients with rosacea: a nationwide case-control study from Taiwan. J Am Acad Dermatol 2015;73:249–54. 10.1016/j.jaad.2015.04.028
    1. Dosal J, Keri J. Rosacea and cardiovascular disease: is there an association? J Am Acad Dermatol 2015;73:308–9. 10.1016/j.jaad.2015.03.031
    1. Russell MB, Rasmussen BK, Thorvaldsen P, et al. . Prevalence and sex-ratio of the subtypes of migraine. Int J Epidemiol 1995;24:612–8. 10.1093/ije/24.3.612
    1. Hernandez-Latorre MA, Roig M. Natural history of migraine in childhood. Cephalalgia 2000;20:573–9. 10.1046/j.1468-2982.2000.00083.x
    1. Dzoljic E, Vlajinac H, Sipetic S, et al. . A survey of female students with migraine: what is the influence of family history and lifestyle? Int J Neurosci 2014;124:82–7. 10.3109/00207454.2013.823961
    1. Volans GN, Castleden CM, Baharuddin NA. The relationship between smoking and migraine. Postgrad Med J 1976;52:80–2. 10.1136/pgmj.52.604.80
    1. Hagen K, Åsberg AN, Stovner L, et al. . Lifestyle factors and risk of migraine and tension-type headache. follow-up data from the Nord-Trøndelag health surveys 1995-1997 and 2006-2008. Cephalalgia 2018;38:1919–26. 10.1177/0333102418764888
    1. Chen TC, Leviton A, Edelstein S, et al. . Migraine and other diseases in women of reproductive age. The influence of smoking on observed associations. Arch Neurol 1987;44:1024–8. 10.1001/archneur.1987.00520220030011
    1. López-Mesonero L, Márquez S, Parra P, et al. . Smoking as a precipitating factor for migraine: a survey in medical students. J Headache Pain 2009;10:101–3. 10.1007/s10194-009-0098-2
    1. Sunhedsstyrelsen, Kræftens_Bekæmpelse, Hjerteforeningen_og_Lungeforeningen Danskernes rygevaner 2018 - nøgletal [Danish] [Internet], 2018. Available:
    1. Hauge AW, Kirchmann M, Olesen J. Trigger factors in migraine with aura. Cephalalgia 2010;30:346–53. 10.1111/j.1468-2982.2009.01930.x
    1. Panconesi A, Bartolozzi ML, Guidi L. Alcohol and migraine: what should we tell patients? Curr Pain Headache Rep 2011;15:177–84. 10.1007/s11916-011-0184-4
    1. Panconesi A. Alcohol and migraine: trigger factor, consumption, mechanisms. A review. J Headache Pain 2008;9:19–27. 10.1007/s10194-008-0006-1
    1. Davis-Martin RE, Polk AN, Smitherman TA. Alcohol use as a comorbidity and precipitant of primary headache: review and meta-analysis. Curr Pain Headache Rep 2017;21:42. 10.1007/s11916-017-0642-8
    1. Ford ES, Li C, Pearson WS, et al. . Body mass index and headaches: findings from a national sample of US adults. Cephalalgia 2008;28:1270–6. 10.1111/j.1468-2982.2008.01671.x
    1. Peterlin BL, Rapoport AM, Kurth T. Migraine and obesity: epidemiology, mechanisms, and implications. Headache 2010;50:631–48. 10.1111/j.1526-4610.2009.01554.x
    1. Vo M, Ainalem A, Qiu C, et al. . Body mass index and adult weight gain among reproductive age women with migraine. Headache 2011;51:559–69. 10.1111/j.1526-4610.2010.01833.x
    1. Yu S, Liu R, Yang X, et al. . Body mass index and migraine: a survey of the Chinese adult population. J Headache Pain 2012;13:531–6. 10.1007/s10194-012-0470-5
    1. Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology 2006;67:252–7. 10.1212/01.wnl.0000225052.35019.f9
    1. Bigal ME. Body mass index and episodic headaches. Arch Intern Med. 2007;167:1964–70.
    1. Keith SW, Wang C, Fontaine KR, et al. . Bmi and headache among women: results from 11 epidemiologic datasets. Obesity 2008;16:377–83. 10.1038/oby.2007.32
    1. Winter AC, Berger K, Buring JE, et al. . Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia 2009;29:269–78. 10.1111/j.1468-2982.2008.01716.x
    1. Giraud P, Chauvet S, Tessy M. Migraine and obesity. is there a link ? Rev Neurol 2013;169:413–8.
    1. Egeberg A, Griffiths CEM, Williams HC, et al. . Clinical characteristics, symptoms, and burden of psoriasis and atopic dermatitis in adults (Epub ahead of print). Br J Dermatol 2019.
    1. Rasmussen BK, Jensen R, Olesen J. Questionnaire versus clinical interview in the diagnosis of headache. Headache 1991;31:290–5. 10.1111/j.1526-4610.1991.hed3105290.x

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit